Titers of SARS CoV-2 antibodies in cord blood of neonates whose mothers contracted SARS CoV-2 (COVID-19) during pregnancy and in those whose mothers were vaccinated with mRNA to SARS CoV-2 during pregnancy

J Perinatol. 2021 Nov;41(11):2621-2624. doi: 10.1038/s41372-021-01216-1. Epub 2021 Sep 25.

Abstract

Objective: We compared neonatal immunity after vaccination against SARS-CoV-2 during pregnancy to that achieved after maternal infection.

Study design: We tested cord blood from women infected with SARS-CoV-2 during pregnancy (group 1, n = 29), women who were vaccinated during pregnancy (group 2, n = 29) and from women not infected and not vaccinated (Group 3, n = 21) for titers of antibodies to both SARS-CoV-2 spike and 'N' proteins.

Results: Seventy-nine women were included: Antibodies against SARS-CoV-2 spike protein were detected in all samples from Group 1 and 2. Antibodies to the 'N' protein were detected in 25/29 samples in Group 1. None of the samples from Group 3 had antibodies to either protein. Mean titers of SARS-CoV-2 antibodies were significantly higher in Group 2 than in Group 1 (p < 0.05).

Conclusions: Neonates born to mothers vaccinated during pregnancy have higher antibody titers and may therefore have more prolonged protection than those born to women infected during pregnancy.

MeSH terms

  • COVID-19*
  • Female
  • Fetal Blood
  • Humans
  • Infant, Newborn
  • Mothers
  • Pregnancy
  • Pregnancy Complications, Infectious*
  • RNA, Messenger
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus

Substances

  • RNA, Messenger
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2